The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...
AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...
In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment. Carlos M. De Castro, MD: I’d love to say we need more studies, studying ...
The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.
Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH studies ...
The US Food and Drug Administration (FDA) recently approved two biosimilars to Soliris for the treatment of two rare diseases — paroxysmal nocturnal hemoglobinuria (PNH), a debilitating and ...
Because paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition, many people may struggle to find the support they need. One patient advocate offers ways to cope. Paroxysmal nocturnal ...
SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...
Paroxysmal nocturnal hemoglobinuria leaves red blood cells more vulnerable to destruction. A common side effect is blood clots, known as thrombosis. This is largely preventable with medication to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results